Managing drug-drug interactions in an HIV-infected patient receiving antiretrovirals, anti-HCV therapy and carbamazepine: a 'tour de force' for clinical pharmacologists

Int J Antimicrob Agents. 2014 Jul;44(1):86-8. doi: 10.1016/j.ijantimicag.2014.04.004. Epub 2014 May 9.

Authors

David M Burger¹, Joop E Arends², Birgit S Jacobs³, Danielle H M van Elst-Laurijsen², Clara T M M de Kanter³, Erik M van Maarseveen⁴, Corrien P W G M Verwey-van Wissen³, Andy I M Hoepelman²

Affiliations

¹ Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: David.Burger@radboudumc.nl.
² Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.
³ Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
⁴ Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.

PMID: 24888870
DOI: 10.1016/j.ijantimicag.2014.04.004

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anticonvulsants / therapeutic use*
Antiviral Agents / therapeutic use*
Atazanavir Sulfate
Carbamazepine / therapeutic use
Cytochrome P-450 CYP3A / metabolism
Drug Dosage Calculations
Drug Interactions
Drug Monitoring
Enzyme Activation / drug effects
Epilepsy / complications
Epilepsy / drug therapy*
Epilepsy / enzymology
Epilepsy / virology
HIV Infections / complications
HIV Infections / drug therapy*
HIV Infections / enzymology
HIV Infections / virology
Hepatitis C / complications
Hepatitis C / drug therapy*
Hepatitis C / enzymology
Hepatitis C / virology
Humans
Male
Middle Aged
Oligopeptides / therapeutic use
Pyridines / therapeutic use
Ritonavir / therapeutic use
Treatment Outcome

Substances

Anticonvulsants
Antiviral Agents
Oligopeptides
Pyridines
Carbamazepine
Atazanavir Sulfate
telaprevir
CYP3A protein, human
Cytochrome P-450 CYP3A
Ritonavir